JP2016510797A5 - - Google Patents

Download PDF

Info

Publication number
JP2016510797A5
JP2016510797A5 JP2015562215A JP2015562215A JP2016510797A5 JP 2016510797 A5 JP2016510797 A5 JP 2016510797A5 JP 2015562215 A JP2015562215 A JP 2015562215A JP 2015562215 A JP2015562215 A JP 2015562215A JP 2016510797 A5 JP2016510797 A5 JP 2016510797A5
Authority
JP
Japan
Prior art keywords
alkyl
het
independently
cycloalkyl
halo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2015562215A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016510797A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2014/055168 external-priority patent/WO2014140313A1/en
Publication of JP2016510797A publication Critical patent/JP2016510797A/ja
Publication of JP2016510797A5 publication Critical patent/JP2016510797A5/ja
Ceased legal-status Critical Current

Links

JP2015562215A 2013-03-15 2014-03-14 大環状塩誘導性キナーゼ阻害剤 Ceased JP2016510797A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP2013055389 2013-03-15
EPPCT/EP2013/055389 2013-03-15
PCT/EP2014/055168 WO2014140313A1 (en) 2013-03-15 2014-03-14 Macrocyclic salt-inducible kinase inhibitors

Publications (2)

Publication Number Publication Date
JP2016510797A JP2016510797A (ja) 2016-04-11
JP2016510797A5 true JP2016510797A5 (enExample) 2017-03-30

Family

ID=50588637

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015562215A Ceased JP2016510797A (ja) 2013-03-15 2014-03-14 大環状塩誘導性キナーゼ阻害剤

Country Status (13)

Country Link
US (1) US9586975B2 (enExample)
JP (1) JP2016510797A (enExample)
KR (1) KR20150133767A (enExample)
CN (1) CN105209040A (enExample)
AU (1) AU2014230125A1 (enExample)
BR (1) BR112015022650A8 (enExample)
CA (1) CA2906262A1 (enExample)
EA (1) EA201591794A1 (enExample)
HK (1) HK1219057A1 (enExample)
IL (1) IL241325A0 (enExample)
MX (1) MX2015012528A (enExample)
SG (1) SG11201507493SA (enExample)
WO (1) WO2014140313A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014140299A1 (en) * 2013-03-15 2014-09-18 Oncodesign S.A Macrocyclic rip2 kinase inhibitors
CA2954186A1 (en) 2014-07-21 2016-01-28 Dana-Farber Cancer Institute, Inc. Imidazolyl kinase inhibitors and uses thereof
AU2017291812B2 (en) 2016-07-05 2023-12-14 Dana-Farber Cancer Institute, Inc. Bicyclic urea kinase inhibitors and uses thereof
WO2018053373A1 (en) * 2016-09-16 2018-03-22 The General Hospital Corporation Uses of satl-inducible kinase (sik) inhibitors for treating osteoporosis
EP3589284A4 (en) 2017-02-28 2020-12-16 The General Hospital Corporation USES OF PYRIMIDOPYRIMIDINONES AS SIK INHIBITORS
EP3391907B8 (en) 2017-04-20 2020-03-04 iOmx Therapeutics AG Intracellular kinase sik3 associated with resistance against anti-tumour immune responses, and uses thereof
WO2019120267A1 (zh) * 2017-12-22 2019-06-27 成都先导药物开发股份有限公司 一种咪唑并[1,2-b]哒嗪大环类激酶抑制剂
JPWO2020027200A1 (ja) 2018-08-01 2021-08-19 小野薬品工業株式会社 軟骨関連疾患治療剤
US11690897B2 (en) 2019-02-04 2023-07-04 The Board Of Trustees Of The University Of Illinois Salt inducible kinase inhibitors for enhancing fertility
CA3168814A1 (en) * 2020-01-31 2021-08-05 Oncodesign S.A. Macrocyclic rip2-kinase inhibitors
AU2023339247A1 (en) * 2022-09-07 2025-03-27 Suzhou Langrui Biopharmaceutical Co., Ltd. Macrocyclic imidazo[1,2-b]pyridazine derivative, preparation method therefor, and use thereof
WO2025252075A1 (en) * 2024-06-04 2025-12-11 Insilico Medicine Ip Limited Novel compounds as salt-inducible kinases inhibitors and uses thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IS2334B (is) 1992-09-08 2008-02-15 Vertex Pharmaceuticals Inc., (A Massachusetts Corporation) Aspartyl próteasi hemjari af nýjum flokki súlfonamíða
ES2166786T3 (es) 1993-10-01 2002-05-01 Astrazeneca Ab Procedimiento i.
US6043358A (en) 1995-11-01 2000-03-28 Merck & Co., Inc. Hexahydro-5-imino-1,4-heteroazepine derivatives as inhibitors of nitric oxide synthases
GB9718913D0 (en) 1997-09-05 1997-11-12 Glaxo Group Ltd Substituted oxindole derivatives
US6369087B1 (en) 1999-08-26 2002-04-09 Robert R. Whittle Alkoxy substituted benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same
US7517882B2 (en) * 2006-09-18 2009-04-14 Polaris Group Protein kinase inhibitors
US7750007B2 (en) * 2006-11-06 2010-07-06 Supergen, Inc. Imidazo[1,2-beta]pyridazine and pyrazolo[1,5-alpha]pyrimidine derivatives and their use as protein kinase inhibitors
WO2008060248A1 (en) * 2006-11-15 2008-05-22 S*Bio Pte Ltd. Indole sustituted pyrimidines and use thereof in the treatment of cancer
CA2722418C (en) * 2008-05-13 2013-09-17 Irm Llc Fused nitrogen containing heterocycles and compositions thereof as kinase inhibitors
MX347765B (es) * 2011-09-30 2017-05-12 Oncodesign Sa Inhibidores macrociclicos de la quinasa flt3.
PT2760453T (pt) * 2011-09-30 2016-08-02 Ipsen Pharma Sas Inibidores macrocíclicos da cinase lrrk2

Similar Documents

Publication Publication Date Title
JP2016510796A5 (enExample)
JP2017529365A5 (enExample)
RU2014117515A (ru) Макроциклические ингибиторы киназы lrrk2
RU2012148246A (ru) 5, 7- замещенные-имидазо[1, 2-с]пиримидины как ингибиторы jak-киназ
RU2012119488A (ru) Конденсированные азиновые производные для лечения заболеваний, связанных с ацетилхолиновым рецептором
JP2019512505A5 (enExample)
JP2016531858A5 (enExample)
JP2017511815A5 (enExample)
JP2015531773A5 (enExample)
JP2019522055A5 (enExample)
JP2016523270A5 (enExample)
JPWO2020122093A5 (enExample)
JP2018514518A5 (enExample)
JP2018515525A5 (enExample)
JP2016530262A5 (enExample)
JP2013523884A5 (enExample)
JP2012511588A5 (enExample)
AR064155A1 (es) Compuestos de inhibidores de fosfoinositido-3 quinasa y metodos de uso
CR20200418A (es) Inhibidores de orginasa y sus mètodos de uso antecedentes
JP2016525136A5 (enExample)
JP2018522034A5 (enExample)
JP2018519343A5 (enExample)
JP2008525417A5 (enExample)
JP2017512833A5 (enExample)
JP2011522866A5 (enExample)